Current challenges in cystic fibrosis screening

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 9, 2003, Pages 1133-1139

  Lyon, Elaine ^a,b,c   Miller, Christine ^a  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

CHRONIC SINUSITIS; CLINICAL FEATURE; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; ETHNOLOGY; FAMILY HISTORY; GENE MUTATION; HUMAN; MASS SCREENING; PANCREATITIS; PRACTICE GUIDELINE; RISK ASSESSMENT; VAS DEFERENS;

ALGORITHMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; DNA MUTATIONAL ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; INFORMED CONSENT; MUTATION; PATIENT EDUCATION; REPRODUCIBILITY OF RESULTS;

EID: 0041834436     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Kerem B, Rommens JM, Buchanan A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1060-1072.
3. Cystic Fibrosis Mutation Database [database on-line]. Toronto, Ontario, Canada: Cystic Fibrosis Genetic Analysis Consortium; 2002. Available at: http://www.genet.sickkids.on.ca/cftr. Updated March 14, 2003.
4. Hannula K, Lipsanen-Nyman M, Kristo P, et al. Genetic screening for maternal uniparental disomy of chromosome 7 in prenatal and postnatal growth retardation of unknown cause. Pediatrics. 2002;109:441-448.
5. Oliveira MC, Reis FJ, Monteiro AP, Penna FJ. Effect of meconium ileus on the clinical prognosis of patients with cystic fibrosis. Braz J Med Biol Res. 2002;35:31-38.
6. Lemna WK, Feldman GL, Kerem B, et al. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med. 1990;322:291-296.
7. Feldman GL, Lewiston N, Fernbach SD, et al. Prenatal diagnosis of cystic fibrosis by using linked DNA markers in 138 pregnancies at 1-in-4 risk. Am J Med Genet. 1989;32:238-241.
8. US National Screening Status Report [database on-line]. Austin, Tex: National Newborn Screening and Genetics Resource Center; 2003. Available at: http://genes-r-us.uthsesa.edu/resources/newborn/screenstatus.htm. Updated March 18, 2003.
9. Cystic Fibrosis Foundation. Living with CF resources page. Available at: http://www.cff.org/living_with_cf/. Accessed September 10, 2002.
10. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J. 2001;18:306-315.
11. NIH Consensus Development Conference Statement. Genetic testing for cystic fibrosis. April 14-16, 1997. Arch Intern Med. 1999;159:1529-1539.
12. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3:149-154.
13. Noone PG, Knowles MR. "CFTR-opathies": disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res. 2001;2:328-332.
14. Kosztolányi G, Malik N, Rutishauser M. Mild CF in a ΔF508/R347H compound heterozygote women: does the manifestation of this genotype differ in the two sexes. Clin Genet. 1996;49:103-105.
15. Raman V, Clary R, Siegrist KL, Zehnbauer B, Chatila TA. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics. 2002;109:E13.
16. Babinski D. Rhinitis in patients with cystic fibrosis. Otolaryngol Pol. 2002;56:23-30.
17. Jequier AM, Ansell ID, Bullimore NJ. Congenital absence of the vasa differentia presenting with infertility. J Androl. 1985;6:15-19.
18. Holsclaw DS, Lober B, Jockin H, Schwachman H. Genital abnormalities in male patients with cystic fibrosis. J Urol. 1971;106:568-574.
19. Chillón M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1991;332:1475-1480.
20. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2002;16:143-156.
21. Viville S, Warter S, Meyer J, et al. Histological and genetic analysis and risk assessment for chromosomal aberration after ICSI for patients presenting with CBAVD. Hum Reprod. 2000;5:1613-1618.
22. Lewis-Jones, DI, Gazvani MR, Mountford R. Cystic fibrosis in infertility: screening before assisted reproduction. Hum Reprod. 2000;15:2415-2417.
23. Rohlfs EM, Zhou Z, Sugarman EA, et al. The I148T CFTR mutation confers a variable phenotype and occurs on multiple haplotypes. Am J Hum Genet. 2001;69(suppl):623.
24. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet. 2002;111:88-95.
25. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000;67:117-133.
26. Ho LP, Samways JM, Porteous DJ, et al. Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. Eur Respir J. 1997;10:2018-2022.
27. Stewart B, Zabner J, Shuber AP, Welsh MJ, McCray PB Jr. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 1995;151(3 pt 1):899-903.
28. Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddess DM. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J. 1990;3:922-926.
29. Lebecque P, Leal T, Godding V. Cystic fibrosis and normal sweat chloride values: a case report. Rev Maladies Respir. 2001;18(4 pt 1):443-445.
30. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998;132:563-565.
31. Pradal U, Castellani C, Delmarco A, Mastella G. Nasal potential difference in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med. 1998;158:896-901.
32. Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Keresmar CM. Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. Pediatrics. 1999;103(4 pt 1):823-826.
33. Lotem Y, Barak A, Mussaffi H, et al. Reaching the diagnosis of cystic fibrosis-the limits of the spectrum. Isr Med Assoc J. 2000;2:94-98.
34. Cuppens H, Buyse I, Baens M, Marynen P, Cassiman JJ. Simultaneous screening for 11 mutations in the cystic fibrosis transmembrane conductance regulator gene by multiplex amplification and reverse dot-blot. Mol Cell Probes. 1992;6:33-39.
35. Strom CM, Huang D, Buller A, et al. Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples. Genet Med. 2002;4:289-296.
36. Grossman PD, Bloch W, Brinson E, et al. High-density multiplex detection of nucleic acid sequences: oligonucleotide ligation assay and sequence-coded separation. Nucleic Acids Res. 1994;22:4527-4534.
37. Gasparini P, Arbustini E, Restagno G, et al. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cycstic fibrosis. J Med Screen. 1999;6:67-69.
38. Gilles PN, Wu DJ, Foster CB, Dillon PJ, Chanock SJ. Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips. Nat Biotechnol. 1999;17:365-370.
39. Heller MJ, Forster AH, Tu E. Active microelectronic chip devices which utilize controlled electrophoretic fields for multiplex DNA hybridization and other genomic applications. Electrophoresis. 2000;21:157-164.
40. Dunbar SA, Jacobson JW. Application of the Luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: a pilot study. Clin Chem. 2000;46:1498-1501.
41. Taylor JD, Briley D, Nguyen Q, et al. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques. 2001;30:661-666, 668-669.
42. Feldmann D, Guittard C, Georges MD, et al. Genetic testing for cystic fibrosis: evaluation of the Elucigene CF20 kit in blood and buccal cells, Ann Biol Clin (Paris). 2001;59:277-283.
43. Bradley LA, Johnson DA, Chaparro CA, Robertson NH, Ferrie RM. A multiples ARMS test for 10 cystic fibrosis (CF) mutations: evaluation in a prenatal CF screening program. Genet Test. 1998;2:337-341.
44. Wine JJ, Kuo E, Hurlock G, Moss RB. Comprehensive mutation screening in a cystic fibrosis center. Pediatrics. 2001;107:280-286.
45. Ellis LA, Taylor CF, Taylor GR. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat. 2000;15:556-564.
46. Bombieri C, Giorgi S, Carles S, et al. A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals. Hum Genet. 2000;106:172-178.
47. Cremonesi L, Carrera P, Fumagalli A, et al. Validation of double gradient denaturing gradient gel electrophoresis through multigenic retrospective analysis. Clin Chem. 1999;45:35-40.
48. De Braekeleer M, Mari C, Verlingue C, et al. Complete identification of cystic fibrosis transmembrane conductance regulator mutations in the CF population of Saguenay Lac-Stain-Jean (Quebec, Canada). Clin Genet. 1998;53:44-46.
49. Ravnik-Glavac M, Atkinson A, Glavac D, Dean M. DHPLC screening of cystic fibrosis gene mutations. Hum Mutat. 2002;19:374-383.
50. Bobadilla JL, Macek M Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat. 2002;19:575-606.
51. Richards CS, Bradley LA, Amos J, et al. Standards and guidelines for CFTR mutation testing. Genet Med. 2002;4:379-391.